Bathing in the 19th Spring Breeze, meeting the opportunity of industrial upgrading - API China's "China Power"

API China API is the oldest exhibition in China's pharmaceutical industry and was founded in 1968. After nearly 50 years of development, API China Exhibition witnessed the development of China's pharmaceutical industry, and it also accompanied generation after generation of Chinese pharmaceutical people to go through ups and downs. Today, the raw material exhibits not only cover 24 major categories of more than 50,000 kinds of APIs, but also includes all excipients, functional ingredients, internal and external packaging materials, and production and testing equipment required for the production of pharmaceuticals and health products. Today's raw materials have become a “one-stop” trade exchange platform for manufacturers of pharmaceuticals and health products at home and abroad, which will provide pharmaceutical colleagues at home and abroad with a comprehensive understanding of the development trends of the Chinese pharmaceutical and health care products industry, meet industry friends, and discover new business opportunities. Provides a great opportunity. It is these unique charms that bring together more than 700 raw material medicines, more than 300 accessories ingredients companies, and over 300 pharmaceutical packaging and 200 pharmaceutical equipment companies. In response to the various "new policies" for pharmaceuticals promulgated in China in 2017, the conference will also hold dozens of forums and seminars in the same period, bringing a wealth of informational meals to colleagues in the medical sector. In November, API China, Xiamen's comprehensive platform, will bring together 50,000 pharmaceutical elites at home and abroad to negotiate business and exchange ideas.

General Secretary Xi Jinping once again emphasized in his 19th report: "Implementing a healthy China strategy." With the issuance of the "Healthy China 2030" plan, the concept of developing a large health industry has gradually deepened into all areas of the pharmaceutical industry. The year 2017 is a critical year for deepening the reform of the pharmaceutical and health system and advancing structural reforms at the supply side. It is also a critical year for improving the quality of Chinese medicines. Improving the quality of medicines, upgrading the overall automation level of the pharmaceutical industry, and upgrading and transforming the environment are just some of the issues. Circles are most concerned about hot issues.

I. API China Raw Material Exhibition - Gathering the “source” power of Chinese pharmaceutical quality improvement

Since 2016, the Chinese pharmaceutical industry has entered an unprecedented period of policy adjustment and market turmoil. With the reform of the review, approval and approval system for medicines, the country’s pharmaceutical policies are frequent, clinical trial data verification, advancement of inspection verification, implementation of GMP audits, promotion of trials for drug marketing license holders, and consistency in the quality and efficacy of generic drugs According to the appraisal, after the appraisal and approving policy for pharmaceutical auxiliary materials and packaging materials, APIs will also be released for management, ushering in the appraisal and approving policies for related issues... A series of policies have been issued, always centering on the “improvement of drug quality and curative effect”. Theme, to promote the transformation of China's pharmaceutical industry from a big producer to a strong country.

To Guoyao Group, Tianyao Group, Shanghai Pharmaceutical Group, Qilu Pharmaceutical, Shijiazhuang Pharmaceutical Group, Puluo Pharmaceutical, Shandong Xinhua, Lukang Pharmaceutical, Tonglian Pharmaceutical, Livzon Group, Ercon Pharmaceutical, Huahai Pharmaceutical, and Haizheng Pharmaceuticals, Baiyunshan, and DSM represented the “traditional magnates” of the Chinese pharmaceutical industry. They will bring their own traditional advantages and new varieties of new research and development to re-appear at the 79th API China Exhibition, using their high-quality products. From pharmaceutical "source" to make its own contribution to the improvement of Chinese pharmaceutical quality.

In recent years, natural extracts have become the fastest-growing products for China's pharmaceutical industry. The API China Exhibition Natural Extract Zone is a specialized exhibition area dedicated to domestic and foreign pharmaceutical preparations, health products, foods, and veterinary medicine companies. It brings together more than 100 extractive manufacturers and agents from home and abroad, including Haotian Pharmaceutical and Xieli Pharmaceutical. Shaanxi Senfu, Xi'an Hongsheng, Shaanxi Jiahe, Ningbo Green Zhijian, Xi'an Xuhuang, Tianjin Topo, Xi'an Tianyi, Guanghan Xicheng, Sichuan Yuxin, Shandong Tianhua, Jilin Hongjiu, Shaanxi Tianxingjian, Shandong Shengxiang Far-range extracts companies will bring their own "competitive products" to the 79th API China Expo to bring the latest natural extract products and information to downstream buyers.

The “2017 China Chemical and Pharmaceutical Industry Annual Summit” co-organized by the China Chemical Pharmaceutical Industry Association's United Nations Reed Reed Exhibition and several major industry associations will be held during the same period. Leaders of relevant regulatory agencies such as the State Council’s Health Reform Office, National Development and Reform Commission, CFDA, and CDE will attend the summit to deliver keynote speeches, interpret hotspot policies, and analyze industry trends. The summit will continue the theme of “Quality, Integrity, and Brand”. The summit will also publish the list of outstanding companies and outstanding product brands in China's chemical and pharmaceutical industry. This list has always been a brand list with significant influence in the industry. The attention and sought after.

Second, PHARMEX - Asia-Pacific Asia's most important accessories exhibition, to witness the quality and efficacy of Chinese generic drugs improve

The consistency assessment of the quality and efficacy of generic drugs is an important measure to promote the structural reform of the supply side of the Chinese pharmaceutical industry. It will drive the transformation of the pharmaceutical industry from China manufacturing to China, the transformation from Chinese speed to Chinese quality, and the transition from Chinese products to Chinese brands. .

As a key factor in improving the quality of generic drugs, accessories products are increasingly valued by pharmaceutical manufacturers. Since 2016, the raw materials will be the world's first pharmaceutical excipients and functional food ingredients brand exhibition --- China International Pharmaceutical Excipients / Functional Food Ingredients Exhibition (PHARMEX Accessories Ingredients Exhibition), the exhibition has been praised by many domestic pharmaceutical companies ! The products displayed at the exhibition included all types of pharmaceutical excipients collected in the Chinese Pharmacopoeia, providing the most efficient, compliant, and diversified product selection for the pharmaceutical, health care, and functional food and beverage industries. The exhibition area exceeded 10,000 square meters. At the 79th Exhibition, Hunan Ercon, Vision Pharmaceutical, Shanhe Pharmaceuticals, Yingmao Pharmaceutical, Qufu Tianli, Gedian Renfu, Colorcon, Ashland, Merck, Gattefoss, Qufu Pharmaceutical, Liaocheng Iowa, New Open Source, Guangdong Runhua, Liaoning Aoke, Guangrao Lifeng, Youhui Pui, Fengli Precision, Dunning Pharmaceuticals, Epson, DFE, Kai Ai Rui, Xiwang Pharmaceutical, Huangshan Capsule, Li Capsules, Honghui capsules, Rosello, Guangsheng capsules, Qingdao capsules, Yuexi capsules, Tianlong capsules, Yuexi capsules, Dongbao biological, Ruibao biological and other top pharmaceutical excipients and functional food ingredients Production companies will bring dozens of new products to the stage.

Generic Drugs Conformity Assessment and Associated Review Evaluation Batch Tour

At present, the consistency assessment work has entered the actual combat stage in an all-round way, the problems are gradually exposed, and many problems such as selection of goods, funds, reference preparations, technical bottlenecks, BE resources, and scale-up production seriously restrict the first batch of evaluation varieties as scheduled before the end of 2018. carry out. The API China generic drug quality and efficacy consistency assessment and associated review and approval exchange meeting has successfully held four stations in Shanghai, Zhenjiang, Huangshan, and Chengdu this year. This time, Xiamen Station will join the China Chemical Pharmaceutical Industry Association and China Pharmaceutical Packaging. The association invites CFDA, CDE, China Inspection Institute, the leaders and experts of the Institute of Drug Control, and two special sessions for injections and oral solid preparations to effectively focus on the practical problems encountered by the company in the work, and to sort out ideas, integrate current mature solutions and developments. Trends help formulation-related companies to actively respond to policy changes, and analyze the problems and difficulties in conformity assessment from different perspectives and latitudes, to ensure the smooth progress of conformance assessment and related review evaluation and approval work, and to join hands with the industry in order to make a difference. Row.

Third, PHARMPACK Pharmaceutical Packaging Exhibition - Asia's first pharmaceutical packaging exhibition, open "drug quality and efficacy" to promote a new chapter

On the evening of October 8, the General Office of the CPC Central Committee and the General Office of the State Council issued the Opinions on Deepening the Reform of the System of Reviewing, Approving and Approving, and Encouraging the Innovation of Drugs and Medical Devices (hereinafter referred to as “opinions”). The “opinions” has been accelerated from the reform of clinical trial management. Listed review approval, promotion of drug innovation and development of generic drugs, strengthening of the whole life cycle management of pharmaceuticals and medical devices, upgrading of technical support capabilities, and strengthening of organization and implementation of six aspects to encourage innovation in pharmaceuticals and medical devices. This indicates that the pharmaceutical industry is moving in the direction of standardization, scale, and branding. This opinion shows that China's appeal for high quality medicine and good curative effect has become increasingly strong from top to bottom. Then, what are the implications of the country's relevant policies in the pharmaceutical and pharmaceutical packaging industries in recent years?

The drug packaging material and drug related review evaluation batch, are you ready?

On August 10, 2016, with the promulgation of the “Announcement on the Relevant Issues for the Examination, Approval, and Approval of Pharmaceutical Substrates and Pharmaceuticals, the development of the pharmaceutical packaging industry ushered in a new stage. The implementation of the related review and appraisal and approval is a concrete embodiment of the administration of the State Food and Drug Administration according to law, and is also an in-depth reflection of the state reform. This reform will eventually increase the effectiveness and safety of drugs, contribute to the improvement of drug quality, and allow the public to enjoy safe drug use. On October 8 this year, the General Office of the CPC Central Committee and the General Office of the State Council issued the Opinions on Deepening the Reform of the System of Reviewing, Approving and Approving the Approval of Drugs and Medical Device Innovations. The comments pointed out that packaging materials are reviewed and approved at the same time when approving applications for drug registration. Packaging materials and quality standards approved by related audits are publicized on designated platforms for selection by relevant companies, and drug product marketing license holders The quality of the packaging material is responsible. This is an important programmatic document issued by the State Council on the outstanding issues facing the current pharmaceutical and medical device innovation after the “Announcement on the Relevant Issues concerning the Examination, Evaluation and Approval of Pharmaceutical Adjuncts and Pharmaceuticals for Pharmaceutical Packaging Materials” in October 2016. Several of the contents will further advance the work of reviewing, approving and approving drugs and pharmaceutical packaging materials. Under this condition, the preparation companies and pharmaceutical packaging companies are also facing pressure and challenges. For manufacturers of pharmaceutical preparations, in order to strengthen the choice of suppliers of pharmaceutical packaging materials, they must also promptly learn about the changes in pharmaceutical packaging materials and conduct research and evaluation on the impact of changes. This undoubtedly puts pressure on the company. . Under this circumstance, if the manufacturer of pharmaceutical preparations can choose a pharmaceutical packaging material manufacturing company with a high product standard, it will be able to help the company reduce the pressure to some extent.

Injectables meet "life and death robberies". What are the opportunities and challenges for injecting agents to re-evaluate in the end?

With the issuance of the Opinions on Deepening the Reform of the Review, Approval System and Encouraging the Innovation of Drugs and Medical Devices, the re-evaluation of injections and other heavy policies were all issued in the “Opinions”. According to the content of the “Opinions”, Articles 11 and 25 all refer to injections and have a heavy influence on injections. "Strictly control oral preparations for injection preparations, strictly control intramuscular injection preparations for intravenous injections, and applications for large-volume injections, small-volume injections, and sterile powder injections for injection will not be approved without obvious clinical advantages" "The re-evaluation of already-listed pharmaceutical injections" once again clarified the country's cautious attitude toward injections. On February 27 this year, Bi Jingquan, Director General of the State Food and Drug Administration, had already proposed to initiate the re-evaluation of the safety and effectiveness of injection medicines. The State Food and Drug Administration subsequently issued announcements on the safety of injections to make injections safer. The problem has become the focus of public opinion. Because the injection channel for injections is mainly medical institutions and cannot be sold outside the hospital, if the injections that enter the re-evaluation list fail to be completed on time, they can only withdraw from the market. Therefore, once the injection re-evaluation starts, the industry will surely usher in a major reshuffle. However, injection packaging is one of the most important factors affecting the safety of injections.

Whether it is drug packaging materials related review evaluation or injection re-evaluation, how to choose a high quality product and a complete certificate of pharmaceutical packaging manufacturers is undoubtedly the most important choice for the formulation company! The 79th PHARMPACK brought together more than 200 outstanding pharmaceutical packaging manufacturing companies. Everyone has a high standard of building a physical factory. Looking for safe and reliable packaging materials, PHARMPACK will take a look at the scene, you will certainly have a lot of harvest! After more than 30 years of development, PHARMPACK Pharmaceutical Packaging Materials Exhibition has become Asia's leading and global pharmaceutical packaging brand event. PHARMPACK exhibited covers the fields of plastic packaging, packaging and printing, pharmaceutical rubber stoppers, caps, aluminum foil, aluminum injection, injection packaging materials, etc., to provide professional, comprehensive, and convenient one-stop packaging for pharmaceutical, health products, cosmetics production companies. Procurement platform and complete packaging solution. Each exhibition attracted nearly 300 excellent pharmaceutical packaging companies and nearly 10,000 professional visitors. At present, it is well known at home and abroad from the likes of Sinopharm Group, Shanghai Pharmaceutical Group, Guangyao Pharmaceutical Group, Shijiazhuang Pharmaceutical Group, Yangzijiang Pharmaceutical, Modified Pharmaceuticals, Fuxing, Hengrui, Qilu, Pfizer, Bayer, Sanofi, Roche and AstraZeneca. Personnel responsible for the production and use of pharmaceutical packaging, R&D, technology, quality, and procurement personnel will all be present.

Fourth, SINOPHEX pharmaceutical equipment exhibition - focus on the pharmaceutical equipment industry for 40 years, help China's pharmaceutical upgrade China's "intelligent" medicine!

SINOPHEX Pharmaceutical Equipment Exhibition takes root in China and serves China. It is making unremitting efforts to promote the exchange of China's pharmaceutical industry and raise the industry's production level. Nearly one thousand Taiwan-made pharmaceutical equipment will be on display at the 79th SINOPHEX. Jiangsu Saideli, Zhongyi Environmental Protection, Jiangbei Machinery, Huada Centrifuge, Daheng Image, Chengyitong, Patek, Dandong Pharmaceutical Machinery, Hengbiao Seri, Giant Energy Machinery, Huading Machinery, Ma Debao, Wenzhou Lihong, Corning, Shanghai and Shanghai Oklahoma, Jiangyin Baoli, Jiyu Machinery, Furuiman, Kunshan close friends and other leading domestic and foreign companies will bring the latest equipment live demonstration.

SINOPHEX Pharmaceutical Equipment Exhibition and API China API held in the same place at the same time, providing thousands of pharmaceutical raw materials, extracts, fine chemicals, accessories ingredients companies face to face to understand the latest technology and equipment, upgrade and improve the quality of their products, a great opportunity, at the same time It also provided a stage for many Chinese manufacturers to make good equipment. It is believed that the pharmaceutical companies and health products manufacturing enterprises will be fully satisfied.

The First China Smart Pharmaceutical 2025 Summit Explores the Road to Smart Medicine with Chinese Characteristics

With the explosive growth of domestic demand in China's health industry, China's pharmaceutical industry is in a critical moment of transformation and upgrading, and equipment manufacturing industry is the cornerstone of industry development. In response to the call of the national "Supply-side Reform," "Made in China 2025," "Healthy China 2030," and other programs, the China Chemical Pharmaceutical Industry Association's Intelligent Pharmaceutical Equipment Special Committee came into being under such circumstances.

The special committee aims to bring together all parties involved in the pharmaceutical and health industry in China to enhance the level of intelligence and automation in China's pharmaceutical equipment, and explore the transformation and upgrading path that meets the actual conditions of the Chinese pharmaceutical industry, so that smart manufacturing can benefit every Chinese pharmaceutical company.

The special committee will hold an inaugural meeting in Xiamen on November 14-15 and hold the “First China Intelligent Pharmaceutical 2025 Summit”. The summit will invite leaders of relevant national authorities and associations and industry-leading research experts to make keynote speeches and bring together advanced pharmaceutical manufacturing companies, equipment manufacturing companies, engineering companies, and system developers in the country to share advanced experiences and cases. , Poly Pharmaceutical colleagues in intelligence, to create China's national conditions in accordance with the pharmaceutical industry 4.0.

Pharmaceutical Environmental Protection Face to Face - Assuring the Sustainable Development of the Pharmaceutical Industry

Environmental upgrades have a huge impact on the pharmaceutical industry. In the face of increasingly stringent environmental protection requirements, green production and pollution control capabilities will become the core competitive elements of future pharmaceutical companies. SINOPHEX will continue to set up a pharmaceutical environmental protection and cleansing zone, and will focus on the pharmaceutical industry's three waste (exhaust gas, waste residue, waste water) treatment technology and pharmaceutical plant environmental protection as a whole solution.

As the brand forum of the exhibition area, the “China International Pharmaceutical Industry Environmental Development Forum” has been successfully held for seven sessions. In line with the purpose of the service industry, the forum has been dedicated to the interpretation of relevant environmental protection policies and regulations, and the promotion of outstanding environmental protection companies and programs. Pharmaceutical companies provide a full range of environmental protection solutions. In this forum, Sinopharm Reed Exhibitions continued to join hands with the Pharmaceutical Association, GuTeng.com and China's outstanding environmental protection companies. Based on the existing content of solving the three wastes issues, the topic of green pharmaceuticals will be increased, and specific issues such as the application of the pollution permit will be given to the pharmaceutical industry. Business answers questions.

In addition, the organizers specially organized the “pharmaceutical environmental protection face to face” event, inviting the environmental protection company to face-to-face exchanges with the pharmaceutical companies, leading to the communication and investigation between the two sides in the early stage, and the exhibition site invited the environmental protection companies to face up to one-on-one to solve technical difficulties and design for the pharmaceutical companies. Environmental protection solutions.

SINOPHEX has been continuously exploring and innovating, hoping to meet the demand for environmental protection equipment from GMP remodeling or new construction projects to the greatest extent possible, and to promote more pharmaceutical companies to meet environmental protection targets and to contribute to the environmental protection of pharmaceuticals in China.

The year 2017 is a crucial year for deepening the reform of the pharmaceutical and health system and advancing supply-side structural reforms. It is also a crucial year for improving the quality of Chinese medicines. General Secretary Xi in the report of the 19th National High School also pointed out the future direction of China's medical and health system reform and its progress. "Care for life, care for health" is the consistent aim of China Pharmaceutical Group and China National Remedy Exhibition. The 79th China International Pharmaceutical Raw Material Drugs/Intermediates/Packaging/Equipment Fair will always uphold its purpose and quality. Together with colleagues in the industry, we will work together to promote the healthy development of the Chinese pharmaceutical industry and realize the healthy Chinese dream.

200CC UTV

200CC UTV,UTV 200CC,200CC Side By Side,200CC UTV For Sale

TAIZHOU NEBULA POWER CO.,LTD , https://www.xingyunutv.com